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Metabolic profiling of 
presymptomatic Huntington’s 
disease sheep reveals novel 
biomarkers
Debra J. Skene1, Benita Middleton1, Cara K. Fraser2, Jeroen L. A. Pennings3, 
Timothy R. Kuchel2, Skye R. Rudiger4, C. Simon Bawden4 & A. Jennifer Morton5
The pronounced cachexia (unexplained wasting) seen in Huntington’s disease (HD) patients suggests 
that metabolic dysregulation plays a role in HD pathogenesis, although evidence of metabolic 
abnormalities in HD patients is inconsistent. We performed metabolic profiling of plasma from 
presymptomatic HD transgenic and control sheep. Metabolites were quantified in sequential plasma 
samples taken over a 25 h period using a targeted LC/MS metabolomics approach. Significant changes 
with respect to genotype were observed in 89/130 identified metabolites, including sphingolipids, 
biogenic amines, amino acids and urea. Citrulline and arginine increased significantly in HD compared to 
control sheep. Ten other amino acids decreased in presymptomatic HD sheep, including branched chain 
amino acids (isoleucine, leucine and valine) that have been identified previously as potential biomarkers 
of HD. Significant increases in urea, arginine, citrulline, asymmetric and symmetric dimethylarginine, 
alongside decreases in sphingolipids, indicate that both the urea cycle and nitric oxide pathways are 
dysregulated at early stages in HD. Logistic prediction modelling identified a set of 8 biomarkers that 
can identify 80% of the presymptomatic HD sheep as transgenic, with 90% confidence. This level 
of sensitivity, using minimally invasive methods, offers novel opportunities for monitoring disease 
progression in HD patients.
Huntington’s disease (HD) is a genetic neurodegenerative disorder caused by an unstable CAG repeat mutation in 
HTT1. It is invariably fatal and there are no treatments targetting the molecular cause of the disease. Although HD 
is diagnosed by the presence of chorea, it is well recognised that HD is not simply a motor disorder. Psychiatric 
disturbance, cognitive decline and sleep/circadian abnormalities all contribute to the insidious decline of HD 
patients. Furthermore, while progressive neurodegeneration of the brain is the best characterised pathological 
hallmark of HD, recent studies have also identified peripheral pathologies as potentially important components of 
HD pathogenesis. These include cardiomyopathy (for references, see2,3) and the pronounced skeletal muscle wast-
ing known as cachexia (Refs 4–7; for other references see3,8). Indeed, cachexia is one of the best recognised signs 
of HD, and appears to be an inevitable sign in HD patients at end stages of disease. Numerous studies have shown 
that weight loss in HD is not secondary to poor nutrition, because HD patients have normal or even higher calo-
rific intake than control subjects (for references, see1). Skeletal muscle dysfunction caused by cachexia and loss of 
motor control causes motor symptoms including dysarthria (inability to talk) and dysphagia (swallowing difficul-
ties). Dysphagia causes the aspiration pneumonia that is one of the major causes of morbidity in HD patients9,10.
The dual presence of chorea and cachexia in HD stimulated the first studies of metabolism in HD in the 1960s. 
Initially it was thought that the chorea caused the cachexia, by using excess energy. It is now known that patients 
with a greater number of CAG repeats exhibit a more rapid loss of weight11, and that cachexia is accompanied 
by changes in gene expression and metabolism that are likely to affect whole-body metabolism and function. 
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Interestingly, cachexia is also a prominent feature of other important diseases such as Alzheimer’s disease and 
cancer, as well as ageing. The mechanism underlying cachexia in all diseases is an increased breakdown of muscle 
protein, which coupled with reduced protein synthesis, leads to overall muscle loss8,12–14. These pathways are likely 
to be disrupted in HD, but the precise mechanism and time course of their disruption is unknown.
Until recently, results from metabolic studies in HD have been very variable and for the most part, insub-
stantial. In early studies, particular attention was paid to lipid and protein metabolites, and although some 
changes were seen, none explained the remarkable wasting of HD patients. Later, direct study of mitochondrial 
function from HD patients and HD mice was undertaken, as have been large-scale metabolomics studies15–17. 
Mitochondrial abnormalities have been implicated in metabolic changes, with reduced mitochondrial function 
found in both HD patient lymphoblasts and HD mouse models18–20. A number of untargeted metabolomic stud-
ies using both humans16,21,22 and HD rodent models23,24 have given interesting results, hinting at, but not always 
revealing, substantial changes in metabolic pathways in HD. Others have found neither changes in energy metab-
olism17 nor carbohydrate, protein or lipid metabolism markers that can differentiate between healthy controls, 
premanifest and stage II/III HD subjects25. Most recently, however, Cheng et al.26 found some changes in met-
abolic profiles of HD patient plasma, Graham et al.27 used NMR spectroscopy to identify a metabolic signature 
of HD, and Patassini et al.28 revealed significant metabolic changes in post mortem human brain. These latest 
studies strongly support the idea that metabolism is deranged in HD, although none show the same changes, and 
some findings conflict with each other27,28. For example, Patassini et al. showed that brain urea levels increased 
significantly, Graham et al. found that they decreased. The differences between each study exemplify the difficulty 
in controlling innate metabolic variation in humans. Nevertheless, there is a consistent theme of dysregulated 
metabolism in all of these studies, particularly with respect to mitochondrial function, nitrogen metabolism and 
lipid metabolism.
Part of the problem with inconsistency between studies lies in the fact that there are considerable challenges 
associated with measuring metabolism in humans. Diet, lighting conditions, sleep/wake status and time of day of 
sampling all have a profound effect on metabolic profiling29. Diet and lighting conditions can be controlled, with 
difficulty in patients, but are more easily managed in animal models. Endogenous circadian variation, however, is 
more problematic for metabolic studies, since this requires highly controlled laboratory conditions -the so-called 
constant routine protocol - to minimise the effect of exogenous factors on circadian rhythmicity30. There is clear 
evidence that circadian rhythms are disrupted in HD patients31,32, mice31,33–35 and sheep33, and that circadian 
regulation of hepatic metabolites in HD mice is abnormal36. It is thus possible that differences in metabolites, 
particularly those that are circadian-regulated, may be missed or masked in samples from subjects with circadian 
defects, if the samples are not collected ‘around-the-clock’. The ideal sampling regime is to take samples at least 
2 hourly from subjects with controlled dietary intake, in dim light over a 24 hour time period. However, such 
sampling regimes are difficult and expensive to conduct in HD patients, and near impossible in mice. For this 
reason, we used a transgenic sheep model of HD, since the feeding and housing conditions of sheep can be well 
controlled, and they are large and robust enough to tolerate multiple blood sampling over the course of ~24 hours.
Metabolomics is the profiling of small-molecule metabolites (<1 kDa). It offers promise for studying not only 
homeostatic regulation but also system perturbations that can be caused by genetic changes, microbes and dis-
ease. Metabolomics has an advantage over other “omics” technologies, in that it assesses directly the metabolic 
changes in an organism, providing a better representation of functional phenotype than changes at the gene, 
transcript, and protein levels37. Metabolic profiling thus has the potential to identify novel biomarkers that could 
be used as diagnostic tools for disease progression or response to treatment. Key metabolomics methodologies 
include nuclear magnetic resonance (NMR), and mass spectrometry (MS)-based technologies (namely liquid 
chromatography (LC)/MS and gas chromatography (GC)/MS, with LC/MS being the most sensitive). Targeted 
metabolomics methods using stable isotope-labelled standards have the advantage over untargeted metabolomics 
methods of allowing the researcher to quantify select classes of metabolites, allowing changes in metabolic func-
tion to be characterised.
Identification of metabolic biomarkers and the metabolic pathways associated with HD progression will aid 
understanding of the pathophysiological mechanisms of the disease, and also spur development of effective ther-
apies by providing sensitive measures of disease progression (for review see ref. 38). With therapeutic trials of 
novel therapies commencing apace in HD, the need for a robust biomarker, has never been greater. The diffi-
culties in studying both people (with their difficult-to-control lifestyles that modulate metabolism) and mice 
(with their fast rodent metabolism and small blood volume for repeated sampling) would be greatly alleviated if 
it were possible to use a large animal model with metabolism similar to that of humans that could be tested in a 
controlled environment. The recently developed ovine model of HD (OVT73) offers such an opportunity39. This 
sheep carries a CAG repeat expansion of 73 in a full-length human cDNA transgene. Lack of overt behavioural 
abnormalities and absence of structural brain changes31, combined with only subtle neuropathology40 and minor 
sex-dependent post mortem changes in cerebellum and liver metabolism41 suggest that, at 5 years of age, this line 
of sheep is still at a presymptomatic stage of HD. Here we used a targeted LC/MS based metabolomics strategy to 
assess biochemical alterations and identify potential biomarkers in presymptomatic HD sheep (hereafter called 
‘HD sheep’).
Results
Targeted LC/MS metabolomics was used to examine the effect of genotype (HD compared to control sheep) on 
plasma metabolite concentrations. Principal component analysis (PCA) of all the samples (n = 24 sheep; 10 con-
trols, 14 HD), time points (n = 13) and metabolites (n = 130) was performed, the PC1 versus PC2 scores matrix is 
presented in Fig. 1a. Abbreviations used for metabolites are shown in full in Table 1. Metabolites (ordered left to 
right in the figure) are 1.SM C16:0; 2. Leucine; 3. Hexadecenoylcarnitine; 4. Valine; 5. Tetradecenoylcarnitine; 6. 
SM C18:0; 7. PC aa C30:0; 8. SM C24:0; 9. SM C16:1; 10. PC aa C28:1; 11. Octadecenoylcarnitine; 12. Sarcosine; 
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13. PC ae C36:5; 14. Isoleucine; 15. SM (OH) C14:1; 16. SM C24:1; 17. PC ae C34:3; 18. PC aa C32:0; 19. SM C18:1; 
20. SM (OH) C24:1; 21. SM (OH) C22:1; 22. PC ae C38:1; 23. PC ae C34:2; 24. SM C26:1; 25. PC ae C32:1; 26. PC 
aa C40:4; 27. PC aa C34:1; 28. SM (OH) C22:2; 29. Tyrosine; 30. Threonine; 31. Hydroxyhexadecenoylcarnitine; 
32. PC ae C36:4; 33. Hydroxyvalerylcarnitine; 34. Methionine; 35. SM (OH) C16:1; 36. Alanine; 37. PC aa C32:3; 
38. lysoPC a C16:1; 39. PC ae C34:1; 40. Phenylalanine; 41. PC ae C32:2; 42. Asparagine; 43. PC ae C30:0; 44. 
PC aa C32:1; 45. PC aa C36:0; 46. SM C26:0; 47. Serotonin; 48. PC aa C40:3; 49. PC aa C38:4; 50. PC ae C40:2; 
51. PC ae C42:4; 52. Glutarylcarnitine; 53. Glutamine; 54. PC ae C38:6; 55. PC aa C40:5; 56. PC aa C38:3; 57. 
Hydroxytetradecenoylcarnitine; 58. PC aa C36:1; 59. PC aa C42:4; 60. PC ae C42:2; 61. PC ae C40:4; 62. PC ae 
Figure 1. Multivariate analysis of targeted metabolomics data. (a) Principal component analysis (PCA) of 
all the data (n = 24 sheep, 10 control, 14 HD; n = 130 metabolites; n = 13 time points). Samples are coloured 
by genotype (black, control; red, HD); (b) OPLS-DA model showing separation by genotype. (c) OPLS-DA 
loading plot of control vs HD. Negative p(corr) values represent decreased and positive p(corr) values 
represent increased metabolite concentrations in HD compared to control sheep. The metabolite bars are 
colour coded according to metabolite class as follows: amino acids and biogenic amines (blue); acylcarnitines 
(green); lysophosphatidylcholine acyl (lyso PC a) (dark orange); phosphatidylcholine diacyl (PC aa) (yellow); 
phosphatidylcholine acyl-akyl (PC ae) (light orange); sphingolipids (SM) (brown). For further details on 
metablolites, see text and Suppl. Table 2.
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Alanine Ala 2.50E-05 1.00E-04 4.20E-01 151.41 ± 2.64 141.89 ± 2.38
Arginine Arg 2.40E-08 4.10E-07 1.40E-01 138.68 ± 1.68 149.45 ± 1.95
Asparagine Asn 8.80E-05 1.10E-17 4.00E-01 26.28 ± 0.47 24.57 ± 0.43
Citrulline Cit 9.50E-24 1.30E-04 6.90E-01 134.79 ± 2.52 161.76 ± 2.37
Glutamine Gln 1.90E-02 9.30E-01 8.00E-01 385.65 ± 4.30 372.94 ± 4.00
Glutamate Glu 7.80E-01 8.40E-04 1.10E-01 40.78 ± 1.35 41.26 ± 1.07
Glycine Gly 3.90E-01 5.80E-14 3.20E-01 1251.40 ± 16.52 1268.56 ± 14.75
Histidine His 7.10E-01 2.20E-01 6.70E-01 62.39 ± 0.71 61.97 ± 0.91
Isoleucine Ile 1.10E-10 9.40E-12 6.20E-01 76.14 ± 1.17 69.68 ± 0.99
Leucine Leu 1.30E-16 1.70E-09 5.30E-01 116.18 ± 1.90 102.19 ± 1.73
Lysine Lys 5.60E-01 5.20E-11 3.20E-01 128.39 ± 3.24 125.95 ± 3.69
Methionine Met 1.30E-06 4.00E-10 3.90E-01 20.94 ± 0.39 19.47 ± 0.36
Ornithine Orn 9.50E-01 4.10E-02 7.10E-01 84.07 ± 1.57 84.19 ± 1.50
Phenylalanine Phe 2.30E-03 1.30E-01 2.90E-01 57.71 ± 0.69 55.31 ± 0.70
Proline Pro 8.20E-01 1.20E-09 2.40E-01 75.45 ± 0.98 75.75 ± 0.93
Serine Ser 8.10E-01 1.30E-09 8.00E-01 126.54 ± 1.67 125.95 ± 1.77
Threonine Thr 2.30E-10 2.20E-11 5.20E-01 160.23 ± 2.38 144.65 ± 4.35
Tryptophan Trp 8.00E-01 4.00E-33 4.40E-01 36.44 ± 0.81 36.66 ± 0.76
Tyrosine Tyr 1.30E-06 7.20E-07 4.20E-01 63.06 ± 1.01 58.90 ± 0.91
Valine Val 5.80E-20 1.60E-05 7.40E-01 164.49 ± 2.69 145.39 ± 2.48
Assymetric dimethylarginine ADMA 1.40E-03 1.80E-02 2.80E-02 2.26 ± 0.03 2.38 ± 0.03
alpha-Aminoadipic acid alpha-AAA 4.70E-02 1.30E-13 5.60E-01 5.03 ± 0.14 5.28 ± 0.18
Carnosine 3.10E-10 9.30E-01 6.90E-01 13.83 ± 0.28 15.12 ± 0.22
Creatinine 3.80E-01 4.90E-01 4.40E-01 179.43 ± 12.55 189.81 ± 10.34
Kynurenine 1.70E-04 5.10E-23 7.90E-01 2.37 ± 0.10 2.58 ± 0.07
Sarcosine 5.60E-20 6.70E-22 5.10E-01 4.70 ± 0.09 4.10 ± 0.10
Serotonin 1.10E-01 6.60E-02 2.30E-01 6.68 ± 0.31 6.00 ± 0.25
Trans-4-hydroxyproline t4-OH-Pro 1.00E-11 2.30E-16 4.00E-01 21.60 ± 0.36 23.63 ± 0.43
Taurine 2.60E-01 2.30E-08 4.90E-01 29.95 ± 1.22 31.25 ± 1.12
Symmetric dimethylarginine SDMA 2.80E-02 3.30E-24 5.40E-02 1.42 ± 0.03 1.47 ± 0.03
Carnitine C0 7.40E-01 1.10E-06 8.40E-01 44.64 ± 1.08 45.07 ± 1.00
Tetradecenoylcarnitine C14:1 1.60E-12 2.70E-10 4.70E-01 0.03 ± 0.00 0.02 ± 0.00
Hydroxytetradecenoylcarnitine C14:1-OH 1.30E-03 2.10E-20 8.40E-01 0.03 ± 0.00 0.02 ± 0.00
Hexadecenoylcarnitine C16:1 1.00E-18 1.00E-17 4.90E-01 0.02 ± 0.00 0.02 ± 0.00
Hydroxyhexadecenoylcarnitine C16:1-OH 1.20E-08 1.20E-24 8.00E-01 0.03 ± 0.00 0.03 ± 0.00
Octadecenoylcarnitine C18:1 1.20E-18 6.80E-23 5.80E-01 0.08 ± 0.00 0.07 ± 0.00
Acetylcarnitine C2 8.50E-01 4.30E-32 6.30E-01 30.26 ± 0.73 30.40 ± 0.80
Malonylhydroxybutyrylcarnitine C3-DC (C4-OH) 2.00E-08 4.90E-09 8.30E-01 0.09 ± 0.00 0.10 ± 0.00
Hydroxyvalerylcarnitine C5-OH (C3-DC-M) 5.10E-03 7.70E-03 6.50E-01 0.08 ± 0.00 0.08 ± 0.00
Glutaconylcarnitine C5:1-DC 4.30E-02 1.40E-04 7.40E-01 0.02 ± 0.00 0.02 ± 0.00
Glutarylcarnitine C5-DC (C6-OH) 1.50E-01 9.90E-01 2.70E-01 0.02 ± 0.00 0.02 ± 0.00
lysoPC a C16:0 4.90E-01 2.70E-01 2.60E-01 28.10 ± 0.34 27.73 ± 0.37
lysoPC a C16:1 8.00E-04 2.60E-04 7.10E-01 1.63 ± 0.03 1.54 ± 0.02
lysoPC a C17:0 1.40E-14 1.20E-02 8.00E-01 2.92 ± 0.08 3.34 ± 0.06
lysoPC a C18:0 7.40E-02 5.50E-05 3.80E-01 18.69 ± 0.32 19.30 ± 0.28
lysoPC a C18:1 9.90E-02 6.50E-01 5.70E-01 24.55 ± 0.38 23.77 ± 0.39
lysoPC a C18:2 4.70E-01 5.70E-03 5.80E-01 18.40 ± 0.39 18.10 ± 0.30
lysoPC a C20:3 6.50E-02 7.90E-05 9.80E-01 0.81 ± 0.02 0.84 ± 0.01
lysoPC a C20:4 8.70E-01 2.40E-02 6.40E-01 4.52 ± 0.09 4.53 ± 0.07
lysoPC a C24:0 4.10E-02 1.90E-03 6.90E-01 0.14 ± 0.00 0.15 ± 0.00
lysoPC a C26:0 7.90E-01 5.80E-03 9.90E-01 0.11 ± 0.00 0.11 ± 0.00
lysoPC a C26:1 7.20E-08 8.00E-02 7.10E-01 0.07 ± 0.00 0.08 ± 0.00
lysoPC a C28:0 5.10E-01 3.50E-01 1.00E + 00 0.20 ± 0.00 0.19 ± 0.00
lysoPC a C28:1 4.90E-11 9.00E-01 9.30E-01 0.48 ± 0.01 0.57 ± 0.02
PC aa C28:1 5.60E-15 4.20E-01 4.20E-01 0.32 ± 0.01 0.29 ± 0.00
PC aa C30:0 8.40E-14 3.40E-01 6.00E-01 1.15 ± 0.03 1.02 ± 0.02
Continued
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PC aa C32:0 2.80E-08 4.50E-02 7.90E-02 4.95 ± 0.12 4.37 ± 0.08
PC aa C32:1 1.20E-03 1.30E-02 9.10E-01 1.80 ± 0.05 1.67 ± 0.03
PC aa C32:3 1.40E-04 4.00E-05 5.20E-01 0.22 ± 0.00 0.21 ± 0.00
PC aa C34:1 1.80E-18 3.60E-01 3.80E-01 73.98 ± 1.84 65.40 ± 1.31
PC aa C34:2 2.60E-05 7.40E-09 5.20E-01 82.67 ± 3.27 77.28 ± 2.72
PC aa C34:3 2.00E-04 1.20E-23 8.00E-01 9.75 ± 0.23 10.37 ± 0.18
PC aa C34:4 8.20E-02 2.10E-05 3.20E-01 0.33 ± 0.01 0.34 ± 0.01
PC aa C36:0 5.30E-06 1.70E-02 8.00E-01 4.41 ± 0.13 4.07 ± 0.07
PC aa C36:1 5.90E-05 8.00E-02 4.10E-01 55.83 ± 0.95 52.70 ± 0.96
PC aa C36:2 3.60E-02 8.60E-06 4.30E-01 83.68 ± 2.29 81.10 ± 1.78
PC aa C36:3 2.00E-01 1.40E-17 7.10E-01 27.83 ± 0.60 28.50 ± 0.45
PC aa C36:4 7.10E-01 1.30E-08 4.00E-01 16.19 ± 0.43 16.05 ± 0.35
PC aa C36:5 4.00E-14 3.10E-18 5.90E-02 3.26 ± 0.08 3.71 ± 0.08
PC aa C36:6 1.10E-02 2.90E-01 4.70E-01 0.17 ± 0.01 0.18 ± 0.00
PC aa C38:0 1.90E-02 2.00E-01 3.90E-01 1.05 ± 0.03 1.01 ± 0.01
PC aa C38:3 1.90E-02 5.20E-01 6.80E-01 7.81 ± 0.18 7.49 ± 0.16
PC aa C38:4 8.50E-04 8.40E-04 5.20E-01 30.98 ± 0.69 29.49 ± 0.47
PC aa C38:5 7.20E-02 5.10E-02 3.40E-01 22.48 ± 0.45 23.18 ± 0.45
PC aa C38:6 5.00E-04 1.50E-04 4.40E-01 8.90 ± 0.25 9.48 ± 0.18
PC aa C40:2 7.90E-01 3.90E-03 5.50E-01 0.07 ± 0.00 0.07 ± 0.00
PC aa C40:3 9.20E-04 8.40E-01 3.20E-01 0.40 ± 0.01 0.37 ± 0.01
PC aa C40:4 2.00E-11 7.90E-01 7.10E-01 3.18 ± 0.07 2.85 ± 0.06
PC aa C40:5 3.30E-03 6.10E-03 3.80E-01 18.40 ± 0.39 17.53 ± 0.41
PC aa C40:6 5.20E-04 1.80E-03 5.20E-01 17.41 ± 0.49 18.45 ± 0.32
PC aa C42:1 1.90E-01 9.50E-01 5.30E-01 0.06 ± 0.00 0.06 ± 0.00
PC aa C42:4 9.50E-02 3.40E-01 6.30E-01 0.07 ± 0.00 0.07 ± 0.00
PC aa C42:5 6.10E-03 2.70E-03 3.90E-01 0.49 ± 0.01 0.47 ± 0.01
PC aa C42:6 4.40E-08 1.40E-04 3.90E-01 0.79 ± 0.03 0.86 ± 0.02
PC ae C30:0 8.40E-04 3.30E-02 8.00E-01 0.29 ± 0.01 0.27 ± 0.00
PC ae C30:2 3.30E-13 4.40E-01 5.60E-01 0.16 ± 0.00 0.18 ± 0.00
PC ae C32:1 2.00E-05 5.10E-01 8.60E-01 0.65 ± 0.02 0.56 ± 0.01
PC ae C32:2 1.50E-04 2.00E-01 5.10E-01 0.48 ± 0.01 0.46 ± 0.01
PC ae C34:0 8.80E-01 7.90E-02 4.10E-01 2.85 ± 0.10 2.83 ± 0.05
PC ae C34:1 5.90E-06 2.90E-02 4.90E-01 5.44 ± 0.14 5.03 ± 0.08
PC ae C34:2 6.20E-12 9.70E-08 5.20E-01 5.19 ± 0.11 4.70 ± 0.08
PC ae C34:3 2.20E-17 5.00E-07 2.90E-01 2.10 ± 0.04 1.87 ± 0.04
PC ae C36:0 7.60E-01 2.20E-04 6.90E-01 1.66 ± 0.06 1.67 ± 0.03
PC ae C36:1 1.60E-03 2.10E-03 8.00E-01 14.65 ± 0.47 13.92 ± 0.25
PC ae C36:2 4.90E-01 3.90E-16 9.50E-01 8.69 ± 0.23 8.80 ± 0.14
PC ae C36:3 5.20E-01 2.20E-14 6.70E-01 3.00 ± 0.08 2.96 ± 0.05
PC ae C36:4 7.90E-06 3.40E-01 2.00E-01 1.49 ± 0.03 1.39 ± 0.02
PC ae C36:5 5.00E-14 1.40E-01 3.00E-01 1.42 ± 0.03 1.27 ± 0.02
PC ae C38:0 1.20E-01 6.20E-01 3.90E-01 0.72 ± 0.02 0.74 ± 0.01
PC ae C38:1 2.60E-44 1.10E-01 9.20E-03 17.19 ± 2.55 7.94 ± 1.18
PC ae C38:2 2.40E-03 3.00E-11 7.10E-01 1.57 ± 0.07 1.48 ± 0.03
PC ae C38:3 8.10E-01 1.50E-07 9.20E-01 1.80 ± 0.06 1.81 ± 0.03
PC ae C38:4 3.00E-01 3.10E-01 3.90E-01 2.63 ± 0.07 2.58 ± 0.04
PC ae C38:5 3.60E-01 7.30E-01 1.50E-01 1.99 ± 0.04 2.03 ± 0.04
PC ae C38:6 1.90E-02 5.80E-01 3.20E-01 1.28 ± 0.03 1.23 ± 0.02
PC ae C40:1 3.00E-07 2.10E-02 5.10E-01 0.22 ± 0.01 0.26 ± 0.01
PC ae C40:2 3.20E-04 6.30E-01 8.60E-01 0.59 ± 0.01 0.56 ± 0.01
PC ae C40:3 4.10E-03 5.80E-01 9.80E-01 0.55 ± 0.02 0.52 ± 0.01
PC ae C40:4 6.00E-03 8.90E-01 8.20E-01 1.05 ± 0.03 1.01 ± 0.02
PC ae C40:5 7.50E-02 8.90E-01 7.60E-01 2.26 ± 0.06 2.34 ± 0.05
PC ae C40:6 5.30E-06 8.60E-01 4.70E-01 1.69 ± 0.05 1.81 ± 0.03
PC ae C42:1 5.10E-01 1.90E-02 6.50E-01 0.09 ± 0.00 0.09 ± 0.00
Continued
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C40:3; 63. PC aa C42:5; 64. PC aa C34:2; 65. PC ae C38:2; 66. lysoPC a C28:0; 67. lysoPC a C18:1; 68. PC ae C36:1; 
69. PC aa C38:0; 70. PC aa C36:2; 71. lysoPC a C16:0; 72. lysoPC a C18:2; 73. SM C20:2; 74. PC ae C38:4; 75. 
Lysine; 76. lysoPC a C26:0; 77. PC ae C36:3; 78. Acetylcarnitine; 79. lysoPC a C20:4; 80. Histidine; 81. Tryptophan; 
82. PC ae C34:0; 83. PC aa C36:4; 84. Serine; 85. PC ae C38:3; 86. Proline; 87.PC ae C44:6; 88. Carnitine; 89. PC 
ae C38:5; 90. PC ae C36:0; 91. Ornithine; 92. PC aa C40:2; 93. PC ae C36:2; 94. PC ae C42:1; 95. PC ae C40:5; 96. 
Glutaconylcarnitine; 97. Creatinine; 98. Taurine; 99. PC ae C38:0; 100. PC aa C34:4; 101. Glycine; 102. Glutamate; 
103. PC aa C38:5; 104. Symmetric dimethylarginine; 105. lysoPC a C20:3; 106. lysoPC a C18:0; 107. PC aa C36:6; 
108. PC aa C36:3; 109. alpha-Aminodipic acid; 110. PC aa C42:1; 111. PC aa C40:6; 112. lysoPC a C24:0; 113. 
PC aa C38:6; 114. PC ae C40:6; 115. Asymmetric dimethylarginine; 116. PC ae C42:3; 117 Kynurenine; 118. PC 
aa C42:6; 119. PC aa C34:3; 120. Malonylhydroxybutyrylcarnitine; 121. Trans-4-hydroxyproline; 122. lysoPC a 
C28:1; 123. PC ae C30:2; 124. PC ae C40:1; 125. Carnosine; 126. lysoPC a C17:0; 127. PC aa C36:5; 128. lysoPC a 
C26:1; 129. Arginine; 130. Citrulline. No separation of genotype was evident in this unsupervised PCA. However, 
orthogonal partial least squares discriminant analysis (OPLS-DA) models, validated by permutation analysis, 
showed good separation between the control and HD sheep (Q2 (cumulative) = 0.790, total amount of variance 
explained in the x matrix (R2X) (cumulative) = 0.687; total amount of variance explained in the y matrix (R2Y) 
(cumulative) = 0.863; Fig. 1b). The p(corr) loading plot for the OPLS-DA model is shown in Fig. 1c and the 
p(corr) values for each metabolite are presented in Supplementary Table 1. Increased concentrations of citrulline, 
arginine, carnosine, t4-hydroxy-proline (t4-OH-proline), kynurenine, asymmetric dimethylarginine (ADMA), 
alpha-aminoadipic acid (alpha-AAA) and symmetric dimethylarginine (SDMA) and decreased concentrations 
of amino acids (particularly the branched chain amino acids), acylcarnitines, sarcosine and sphingolipids were 
observed in the HD sheep. There was a significant correlation between the p(corr) values and genotype False 
Discovery Rate (FDR) values obtained from the ANOVA analyses of the metabolite concentrations. The top 20 
metabolites at the extreme ends of the loading plot (Fig. 1c) also showed the most significant effect of genotype in 
the ANOVA analyses of the metabolite concentrations (Table 1). In total, 89 of the 130 metabolites (68%) changed 
significantly with respect to genotype. Of these, 25 metabolites showed increased and 64 metabolites showed 
decreased concentrations in HD sheep compared to controls (FDR < 0.05; Table 1). A heat map combined with 
hierarchical clustering of these metabolite profiles across the 24 h period is shown in Supplementary Figure S1.
Amino acids. Of the 20 amino acids quantified, only citrulline and arginine had significantly increased levels 
in HD compared to control sheep (Fig. 2). Indeed, of all 130 metabolites quantified, citrulline showed the most 
marked change (FDR < 1.0E-23) in the HD sheep. Citrulline and arginine are both part of the urea cycle (Fig. 3). 
However ornithine, also part of the urea cycle, showed no significant differences between the genotypes (Fig. 2). 
Of the 20 amino acids measured, 10 had significantly reduced concentrations in the HD sheep, with the branched 
chain amino acids (valine, leucine, isoleucine) showing the most pronounced effect of genotype followed by thre-










PC ae C42:2 1.90E-02 4.20E-01 8.10E-01 0.13 ± 0.00 0.12 ± 0.00
PC ae C42:3 8.50E-05 1.30E-07 3.80E-01 0.13 ± 0.00 0.14 ± 0.00
PC ae C42:4 6.70E-03 7.80E-01 1.90E-01 0.07 ± 0.00 0.06 ± 0.00
PC ae C44:6 5.80E-01 4.90E-01 5.80E-01 0.05 ± 0.00 0.05 ± 0.00
SM (OH) C14:1 1.40E-09 8.30E-01 5.00E-01 7.39 ± 0.13 6.74 ± 0.10
SM (OH) C16:1 5.90E-05 8.70E-01 4.20E-01 11.60 ± 0.24 10.88 ± 0.18
SM (OH) C22:1 6.00E-08 8.40E-01 3.20E-01 27.60 ± 0.54 25.07 ± 0.47
SM (OH) C22:2 3.50E-07 8.00E-01 5.40E-01 16.40 ± 0.34 15.01 ± 0.26
SM (OH) C24:1 7.60E-08 6.50E-01 5.40E-01 1.73 ± 0.04 1.56 ± 0.03
SM C16:0 1.10E-17 5.20E-01 3.40E-01 94.90 ± 1.61 82.17 ± 1.35
SM C16:1 2.50E-12 7.10E-01 3.20E-01 5.51 ± 0.10 4.93 ± 0.10
SM C18:0 4.80E-13 2.00E-01 2.40E-01 19.51 ± 0.46 17.21 ± 0.29
SM C18:1 1.20E-09 8.30E-01 1.70E-01 5.92 ± 0.14 5.35 ± 0.09
SM C20:2 6.60E-01 9.80E-01 9.30E-01 0.13 ± 0.00 0.13 ± 0.00
SM C24:0 1.20E-09 8.00E-01 2.70E-01 15.38 ± 0.33 13.73 ± 0.24
SM C24:1 1.90E-09 4.30E-01 3.80E-01 33.71 ± 0.82 29.89 ± 0.58
SM C26:0 4.30E-03 8.90E-01 5.00E-01 0.32 ± 0.01 0.30 ± 0.01
SM C26:1 5.20E-04 6.90E-01 4.00E-01 0.24 ± 0.01 0.21 ± 0.01
Table 1.  ANOVA analyses of the metabolite concentrations. Individual metabolite levels were analysed in 
R version 3.1.2 using the linear models and ANOVA methods. Linear models were fitted to the genotype and 
time of day, with the animal as covariate. Significant differences for time of day, genotype, and their interaction 
were determined using 2-way ANOVA. P-values were corrected for multiple comparisons according to the 
Benjamini-Hochberg False Discovery Rate (FDR). Metabolites were considered as significant at a FDR cut off  
<0.05 (highlighted in bold). 24 h mean values (±SEM), derived from all the time points, for both the control 
and HD sheep are also shown.
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The ratios of Cit/Arg, Cit/Orn and Orn/Arg were calculated as indicators of nitric oxide synthase (NOS), 
ornithine carbamoylphosphate transferase and arginase activity, respectively. All of the ratios were significantly 
different (FDR < 1.0E-12) between the HD and control sheep, with higher Cit/Arg and Cit/Orn ratios and a lower 
Orn/Arg ratio in the HD sheep.
Biogenic amines. Seven of the 9 quantified biogenic amines changed significantly with respect to genotype. 
Six of these increased significantly in HD sheep. These were trans-4-hydroxyproline (t4-OH-proline) >carnosine 
>kynurenine >ADMA >SDMA >alpha-AAA (Fig. 5). By contrast, only sarcosine showed significantly reduced 
levels (FDR < 1.0E-19) in the HD sheep.
Acylcarnitines. Most of the measured acylcarnitines (8 of 11) were significantly altered by genotype, 6 
showing reduced concentrations and two (hydroxybutyrylcarnitine (C3-DC(C4-OH)) >glutaconylcarnitine 
(C5-1-DC)) showing increased concentrations (Table 1).
Sphingolipids. All, but one (SM C20:2), of the 14 sphingolipids (93%) quantified were significantly reduced 
in the HD sheep compared to the controls (Table 1). These 13 sphingolipids included both hydroxylated (n = 5) 
and non-hydroxylated (n = 8) ceramide phosphocholines (sphingomyelins). Figure 6 presents the 24 h mean data 
of each of the 15 sphingolipids in the HD and control sheep.
Glycerophospholipids. Of 75 quantified glycerophospholipids (n = 62 phospholipids; n = 13 lysophos-
phatidylcholines), 44 phospholipids (71%) and 5 lysophosphatidylcholines (38%) were significantly altered in 
the HD sheep (Table 1). There was no consistent pattern to the direction of change with some showing markedly 
reduced levels (e.g. PC ae C38:1; PC aa C34:1; PC aa C30:0; PC aa C28:1; PC aa C40:4) and some showing elevated 
levels (e.g. PC aa C36:5; lysoPC a C17:0; PC ae C30:2) in the HD sheep (Table 1).
Urea. The hourly plasma concentrations of urea nitrogen in the control and HD sheep are presented in Fig. 2. 
Urea nitrogen levels were significantly higher (FDR < 1.0E-18) in the HD sheep (7.0 ± 0.08 mmol/L) compared 
to the control sheep (6.8 ± 0.09 mmol/L).
Quantitative enrichment analysis (QEA). Quantitative enrichment analysis (QEA) was performed 
using MetaboAnalyst 3.0 (www.metaboanalyst.ca; ref. 42). The top 5 metabolite pathway-associated metabolite 
Figure 2. Twenty four-hour profiles of urea cycle metabolites. (a) Arginine, (b) urea, (c) ornithine, 
(d) citrulline. Mean (±SEM) plasma levels in control (◾, solid line) and transgenic HD (○, dashed line) 
sheep are presented, corrected for circadian phase using each sheep’s dim light melatonin onset (DLMO), 
annotated as zero (=20.9 ± 0.9 h (mean ± SEM) ≈21.00 h). Significantly increased arginine, urea and citrulline 
concentrations were observed in the HD sheep compared to the controls (FDR < 0.05).
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sets were aspartate metabolism; arginine and proline metabolism; valine, leucine and isoleucine (branched chain 
amino acids) degradation; fatty acid metabolism and urea cycle (Supplementary Figure S2). No pathways, how-
ever, were significantly enriched following FDR correction.
Prediction modelling. Using logistic prediction modelling, we developed eight models with increasing per-
formance by adding one metabolite at a time to the existing model until no further improvement was obtained 
(Fig. 7). The simplest of these was based only on citrulline (model_1, AUC = 0.664, sensitivity = 17.7%). Stepwise 
improvement combined with leave-one-sheep-out cross-validation resulted in a final model (model 8) based 
on eight markers (citrulline, valine, PC aa C40:4, PC aa C36:5, lysoPC a C17:0, SM (OH) C24:1, threonine, tet-
radecenoylcarnitine (C14:1)) with an AUC of 0.938. This model allowed for 80.1% sensitivity at 90% specific-
ity (Supplementary Table 2). In the HD sheep citrulline, PC aa C36:5 and lysoPC a C17:0 were significantly 
increased and valine, PC aa C40:4, SM (OH) C24:1, threonine and tetradecenoylcarnitine (C14:1) were signifi-
cantly decreased compared to the control sheep.
In order to determine which time point best discriminates the control and HD groups, AUC values for the 
models were determined for each time point. For the final (best performing) model (model 8), the 05:00 h time 
point gave the best discrimination between the genotypes (AUC = 0.986). Times 07:00 h and 09:00 h perform as 
second/third best (AUC = 0.971 for both). For comparison, the AUC for all time points combined is 0.938, so the 
additional discrimination for these time points is relatively small. When other models were also considered, time 
Figure 3. The urea cycle and nitric oxide (NO) pathway in health and disease. (a) The major constituent 
parts of the metabolic pathway that comprises the urea cycle and NO pathway. (b) Changes in metabolites of the 
urea cycle and NO pathway in HD sheep. Significant increases are shown in red font. Abbeviations: NO = nitric 
oxide, ADMA = asymmetric dimethylarginine
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points 05:00 h and 07:00 h perform as best and second-best respectively, in the majority of the models. The time 
point 05:00 h (before dawn) therefore seems the most discriminating between the genotypes.
Discussion
Using targeted LC/MS based metabolomics we have identified significant metabolic alterations in the HD sheep. 
The metabolites we identified include metabolites that have been identified previously as being involved in HD 
pathology (kynurenine, urea) or suggested as biomarkers for HD (branched chain amino acids). Together our 
data strongly support the idea that a plethora of metabolic changes occur very early (and even presymptomati-
cally) in HD, and that these are likely to contribute deleteriously to its progression.
Marked elevation in the amino acids citrulline and arginine, both components of the urea cycle, were observed 
in the HD sheep. Our findings corroborate previous studies reporting raised blood citrulline levels in patients 
with HD and in two mice models (R6/2 and HdhQ150; ref. 43) and are consistent with abnormalities in the 
urea and NO cycles. A suggested mechanism is that disruption of CCAAT-enhancer-binding proteins (C/EBP) 
activity by mutant huntingtin44 causes suppression of the expression of two key enzymes (argininosuccinic acid 
synthetase and argininosuccinase acid lyase) of the urea cycle44. In addition to being produced in the urea cycle 
from ornithine and carbamoyl phosphate, citrulline is derived from arginine as a by-product of NO synthesis via 
NO synthase. The increased arginine observed in the HD sheep may thus contribute to raised citrulline and NO 
levels (Fig. 3b). Although we could not measure NO levels using the samples we collected for LC/MS analysis, 
it would be interesting to measure NO levels in any future studies. Raised levels of both arginine and NO have 
been implicated in HD progression25. Dietary supplementation of arginine in HD mice hastens disease progres-
sion (demonstrated by increased weight loss and abnormal motor function; ref. 43). Furthermore, in a number 
of other studies NO and NOS have been linked either directly or indirectly to many aspects of HD pathology, 
such as oxidative stress45, mitochondrial dysfunction46,47, platelet signalling48 and peripheral vasodilatation49. The 
significant increase in the Cit/Arg and Cit/Orn ratios in the HD sheep suggest that abnormal activation of the 
enzymes nitric oxide synthase (NOS) and ornithine carbamoylphosphate transferase is likely. Until we conducted 
the analysis, we did not know that the urea cycle or NO system might be perturbed in the HD sheep, and we could 
not measure NO levels in the plasma retrospectively. The decreased Orn/Arg ratio suggests suppression of argin-
ase (ARG) activity in the HD sheep. Together these data point to abnormalities in the urea cycle and NO cycle, as 
has been suggested in HD mice44,49,50. Interestingly, a low protein diet (17%) restores urea cycle activity and ame-
liorates symptoms in HD model mice43. In support of possible NO disturbances in HD, the HD sheep also had 
significantly raised levels of ADMA and SDMA compared to control sheep. ADMA is an endogenous inhibitor of 
NOS (inhibiting all 3 isoforms of NOS; ref. 51; Fig. 3b). SDMA, the structural isomer of ADMA, competes with 
the arginine transporter, and regulates NOS by limiting amounts of ADMA52. ADMA, but not SDMA, is hydro-
lysed by dimethylarginine dimethylaminohydrolase (DDAH) to form dimethylamine (DMA) and citrulline. Thus 
an increase in ADMA could cause/contribute to an increase in citrulline. Raised plasma levels of ADMA and 
SDMA are associated with a range of conditions, including ageing, cardiovascular disease, hypercholesterolaemia 
and insulin resistance/hyperglycaemia (for review, see ref. 53). Finally, there is evidence for abnormal processing 
of arginine playing a role in HD54.
A prominent finding in the current study was the marked decrease in plasma sphingolipids in HD sheep com-
pared to controls. Progressive neurodegeneration in HD involves loss of both grey and white matter volume and 
myelin breakdown. This may correlate with reduced sphingolipids in the circulation. Sphingolipids are involved 
in the structure and function of cell membranes in the brain55,56 and are associated with a plethora of biologi-
cal functions57. Dysfunction in the synthesis and/or breakdown of sphingolipids would be expected to have a 
major impact on neuronal function, neurotransmitter receptors, synaptic transmission and cellular signalling, in 
addition to the myelination/oligodendrocyte deficits. There is accumulating evidence that NO and sphingolipids 
interact in reciprocal pathways, leading to regulation of activity and expression of enzymes involved in signalling 
events from both pathways (for review, see ref. 58). Using an untargeted metabolomics approach, sphingolipids 
have also been identified recently as dysregulated in an HD cell line model59.
Figure 4. Comparison of 24-h profiles of branched chain amino acids in normal and transgenic HD sheep. 
(a) Leucine, (b) isoleucine, (c) valine. Data are mean (±SEM) plasma levels in control (◾, solid line) and HD 
(○, dashed line) sheep. Data are corrected for circadian phase using each sheep’s dim light melatonin onset 
(DLMO) annotated as zero (20.9 ± 0.9 h (mean ± SEM) ≈21.00 h). Significantly reduced branched chain amino 
acids were observed in the HD sheep compared to controls (FDR < 0.05).
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Notwithstanding the fact that it may be difficult to link brain processes with plasma biomarkers, there are 
numerous studies to suggest that metabolic changes in the periphery reflect a disease signature. Peripheral sphin-
golipids have been reported to be predictors of cognitive decline, low sphingomyelin levels being associated with 
a faster rate of cognitive decline60,61. In an effort to understand the relationship between central and peripheral 
processes, metabolic profiling has been performed on both CSF and plasma taken from the same individuals 
(controls, mild cognitive impairment and Alzheimer’s disease62). These authors showed that approximately 30% 
of the metabolic pathways altered in the CSF of the study groups were also altered in the plasma, inter alia sphin-
golipid transport pathways were significantly affected in both CSF and plasma, validating plasma as a useful 
biofluid for neurodegenerative disease research. However, even if these long chain sphingolipids do not cross the 
blood brain barrier and there is no direct correlation between CSF and peripheral levels, it does not mean that 
plasma sphingolipids will not be useful as biomarkers in HD prognosis. As second messengers there are several 
mechanisms by which sphingolipids could directly or indirectly affect HD disease progression, as has been shown 
for Alzheimer’s disease63,64. These findings, combined with the present study, suggest that sphingolipids may be 
interesting general markers of neurodegeneration. It would be particularly interesting if this were the case, since 
Figure 5. Comparison of 24-h profiles of biogenic amines in normal and transgenic HD sheep. (a) Trans-
4-hydroxyproline (t4-OH-proline), (b) carnosine, (c) kynurenine, (d) asymmetric dimethylarginine (ADMA), 
(e) symmetric dimethylarginine (SDMA) and (f) alpha-aminoadipic acid (alpha-AAA). Mean (±SEM) plasma 
levels in control (◾, solid line) and HD (○, dashed line) sheep are presented, corrected for circadian phase using 
each sheep’s dim light melatonin onset (DLMO), annotated as zero (=20.9 ± 0.9 h (mean ± SEM) ≈21.00 h). All 
these biogenic amines were significantly increased in HD sheep compared to controls (FDR < 0.05).
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there is currently no structural31 and only subtle histological40 evidence to show neurodegeneration in these HD 
sheep. If plasma sphingolipids herald incipient neurodegeneration, it may be useful as a predictive biomarker. 
This would be a particularly useful aspect of the metabolome on which to focus in the future.
The present findings support our previous observations of dysregulation of a number of nitrogen metabolis-
ing genes (Ahcy, Ass1 and Arg1) that might contribute to HD symptoms36. Dysregulation of Ass1 and Arg1, key 
components of the urea cycle, could lead to the accumulation of toxic metabolites that could exacerbate HD neu-
ropathology65,66. Interestingly, urea cycle abnormalities characterized by hyperammonemia, high blood citrulline, 
and suppression of urea cycle enzymes have already been shown in two mouse models of HD as well as in HD 
patients44,67. Finally, elevated levels of urea have been found in post-mortem HD brain28.
Ten other amino acids measured were significantly reduced in the HD sheep. Of particular note were the 
proteinogenic branched chain amino acids (leucine, isoleucine and valine). These have previously been identi-
fied as possible biomarkers for HD68,69. That study, using a large cohort of patients with HD at different stages 
Figure 6. Comparison of plasma concentrations of 15 sphingolipids in normal and transgenic HD sheep. 
Panels show sphingolipids with concentrations between 2 and 100 μM (a) or up to 2 μM (b). Data are 24 h mean 
values (±SEM) derived from all the time points. Most (14/15) of the sphingolipids were significantly reduced in 
HD sheep compared to controls (* FDR < 0.05).
Figure 7. Receiver operating characteristic plots of the 8 prediction models. Models were improved stepwise 
by including an additional metabolite until no more gain in AUC could be obtained during cross-validation. 
The metabolites used in each model are shown in Supplementary Table 2 . 
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of the disease, showed a significant reduction of plasma branched chain amino acids in HD, which correlated 
with weight loss and disease progression. Leucine was of particular interest because it was significantly reduced 
in patients at an early stage of the disease, as well as in presymptomatic individuals. Leucine is a well-known 
activator of mTor (mammalian target of rapamycin2), which regulates protein synthesis and whose inhibition 
results in increased autophagic proteolysis. It is particularly notable that the branched chain amino acids were 
decreased in the HD sheep that are all at least 3 years from disease onset. (This study was done in 5 year old sheep 
that are now 7-8 years old and still showing no symptoms; unpublished data; AJM). This supports the suggestion 
that branched chain amino acids may be a useful biomarker for HD. Consistent with our findings, another group 
suggested that asparagine and serine (revealed in all of our statistical analyses) could be considered as potential 
plasma HD biomarkers70.
Our decision to use a targeted rather than an untargeted metabolomics approach was pragmatic, based on 
the large number of samples generated by round-the-clock sampling (13 samples for each animal, n = 24 sheep) 
and the cost/time involved, which is much greater for untargeted than targeted metabolomics analysis. While 
untargeted metabolomics analysis may generate additional metabolites, without the intensive workup necessary 
to identify these metabolites according to the Metabolomics Standards Initiative (www.metabolomics.msi.org; 
ref. 71), they would only remain as ‘features’ or ‘putative metabolites’ with mass-to-charge ratio (m/z) informa-
tion. This is less useful than the identified metabolite that is available with the targeted approach. By analysing our 
samples using targeted metabolomics analysis we obtain absolute concentrations of the metabolites (as opposed 
to relative expression in untargeted analysis). Although the total number of metabolites measured using targeted 
metabolomics analysis is relatively small, the method is nevertheless extremely useful for understanding changes 
in metabolic function in different physiological and pathological states. In addition, the use of a fully validated 
method that is selective and reproducible with low CV gives confidence that the metabolites identified by this 
method are real and that the data generated can be replicated in other facilities.
Taking advantage of being able to measure metabolites from 5 different classes and using logistic prediction 
modelling, an optimised marker panel containing 8 biomarkers was identified in our metabolite panel. These 
metabolites (citrulline, valine, PC aa C40:4, PC aa C36:5, lysoPC a C17:0, SM (OH) C24:1, threonine, C14:1) 
come from 4 of the 5 metabolite classes quantified. With this panel of 8 metabolites, we were able to identify 80% 
of the HD sheep as transgenic, with 90% confidence. Identifying 8 biomarkers that can be measured reliably and 
relatively easily makes this a method that could be adopted by a large number of laboratories and translated to 
studies in human subjects.
As well as providing evidence for the presence of metabolic biomarkers of HD, the changes we see strongly 
validate the use of the OVT73 sheep as a model of HD. The particular value of a sheep model of HD in general, 
and these sheep in particular, is that they can be monitored longitudinally to determine if/how these metabolic 
changes progress over time. If so, the metabolic changes may be useful as a state or rate markers that could even-
tually be used to monitor disease progression. We identified more dysregulated metabolites than have been iden-
tified in any other study. This is likely to be because of our sampling regime. There has never been a study using 
an HD animal model in which around the 24 h clock samples have been taken under well-controlled conditions. 
It is interesting to note that, while no study in patients shows changes in all of the metabolites we identified, all of 
the metabolites or metabolic families have been identified previously as being dysregulated in HD. Clearly, the 
set of metabolites we have identified as potential biomarkers will also need to be measured in HD patients under 
well-controlled conditions, to confirm the findings from our sheep model. The need for a robust biomarker, how-
ever, has never been greater. Currently, clinical outcome measures are used for tracking the progression of HD. 
Measures such as the unified HD rating scale (UHDRS) are well established and widely used. They are, however, 
subjective, and prone to rater variability. Furthermore, because they are based on symptomatic assessment, they 
cannot be used to detect preclinical changes in gene mutation carriers. Much progress has been made in recent 
years in developing and evaluating biomarkers for HD, most notably in the fields of quantitative clinical measures 
and cognitive measures, but the development of objective and reliable disease-specific biomarkers that can be 
rapidly measured become immeasurably important once clinical trials for therapies begin. This is more important 
now than it has ever been, since several novel therapeutic candidates are in ongoing or planned clinical trials, 
including the first clinical trial of a gene knockdown therapy using an antisense oligonucleotide therapeutic called 
Ionis-HTTRx 72.
In summary, the metabolic profiles reveal clear urea cycle and NO system disturbances in presymptomatic 
HD sheep. A panel of 8 biomarkers that confidently detects disease in presymptomatic HD sheep is proposed. A 
biomarker that can be used to define the stage or track the progression of disease would be invaluable for meas-
uring therapeutic effects in HD.
Materials and Methods
Animals. Twenty four merino rams (Ovis aries) were used for this study. HD transgenic (OVT73 line) and 
control rams were maintained outdoors as a mixed transgenic/normal ram flock in PC1-certified paddocks 
(PC1 Large Grazing Animal Facilities) at the South Australian Research and Development Institute (SARDI) 
in accordance with AEC approval #27/13 (Primary Industries and Regions South Australia; PIRSA) and Office 
of the Gene Technology Regulator (OGTR) approval NLRD-1037/2003. They were born and raised on this site 
and were 5 years old [at the time of this study]. Up to the time of blood sampling, rams were grazed on pas-
ture ad libitum, with feed supplementation during seasonal periods when feed-on-offer was low. For circadian 
blood sampling, 24 (14 HD and 10 control) rams were transported from SARDI to the Preclinical Imaging and 
Research Laboratory (PIRL) of the South Australian Health and Medical Research Institute (SAHMRI) at Gilles 
Plains, South Australia. Animal husbandry and blood sampling was performed in accordance with AEC approv-
als #07/14 (PIRSA) and SAM93 (SAHMRI). For at least 4 weeks prior to transport the rams were fed a ration of 
cereal hay and a pea/barley mixture supplement that was continued once the sheep had been relocated to PIRL. 
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The aim was to ensure minimal dietary change throughout the period prior to sampling when sheep were moved 
from one site to the other.
Animal husbandry (acclimatisation, feed adaption and fasting). Sheep were acclimatised at 
SAHMRI for three weeks following transfer from SARDI (May, 2014). The holding areas had ambient light. 
Sheep were fed on a diet of feed that included a combination of Oats/Lucerne/Vetch 2013 season hay and Ewe 
replacement sheep nuts (Laucke Mills). Sheep were transferred into undercover pens for a minimum of one week 
acclimatisation to human contact. Sheep were transferred to indoor holding on the day prior to cannula insertion. 
They were housed in individual metabolic crates elevated approximately one metre above the floor.
During indoor acclimatisation the light cycle matched the outdoor light/dark cycle. At the time sampled, this 
was ~10 h light; 14 h dark (10 L:14D). On the day of cannulation, the lights were turned off in the evening (at sun-
set; ~1710 h clock time), and remained off until the end of the blood collection period ~45 hours later (see below). 
The sheep remained in the crates overnight following removal of the catheters at the end of the blood collection 
period. They were then transferred to undercover outdoor pens for up to 48 hours, and from there to a paddock.
Light monitoring. The amount of light in the indoor holding room and the undercover outdoor pens was 
monitored continuously using HOBO temperature/light monitors (Tempcon Instrumentation Ltd., Arundel, 
UK), with HOBOs positioned throughout the sampling room (n = 4) and undercover pens outside (n = 4). Lux 
meter readings (in direction of gaze, lux meter held in vertical plane) were collected during blood sampling (day-
time; dusk, night, dawn; daytime). Blood sampling in the indoor holding room occurred with lights out. A red 
headtorch light was used to collect specimens; there were no lights in the corridor, and a blackout curtain hung 
over the door.
Placement of jugular cannula. The sheep were fasted overnight prior to the placement of the jugular 
cannula. Feed was then provided ad libitum until the end of that day  (i.e. end of the day before blood sampling 
commenced). From that night onwards and during the 25 hour blood sampling period (14.00 h–15.00 h) food was 
withheld but water was available ad libitum. The sheep were fed immediately on completion of the blood sampling 
period once the catheter had been removed.
The sheep were conscious throughout the cannula implantation (BD AngioCath, 2.1 × 133 mm). Sheep were 
administered a local anaesthetic (2–4 mL Lignocaine 20 subcutaneously; Ilium, Australia) after the neck was 
clipped and sprayed with Povidone Iodine (100 mg/mL Apex Laboratories, Australia). The jugular vein was 
located and a cannula surgically inserted. The cannula tubing was long enough to be looped around one side of 
the neck and secured to the back of sheep. A three-way tap was connected to the end of the catheter tubing. All 
sheep were given a dose of antibiotic (10 mL Rilexine 150, subcutaneously; Virbac, Australia). The sheep were 
returned to their pens, and when all sheep had recovered, they were fed. Their food was removed when staff left 
for the day.
Around-the-clock sample collection. Blood collection commenced at 14:00 h the day following place-
ment of the cannula. The blood samples were collected on the hour (±5 min) hourly for 25 h (blood collection 
completed at 15:00 h). For blood sample collection via the indwelling cannula, an appropriate dead volume of 
blood was withdrawn and discarded. Following this, 10 mL of blood was withdrawn into a fresh syringe and 
transferred to lithium heparin tubes, which were gently inverted 5–8 times. The cannula was flushed with 10 mL 
of normal saline or heparinised saline (5 IU/mL heparin; Sterisafe, Pfizer, Australia) as required. The samples were 
centrifuged immediately at 3200 rpm (1620 g) for 10 minutes at 4 °C and split into aliquots. The plasma aliquots 
were placed immediately in liquid nitrogen or directly into a −80 °C freezer if no liquid nitrogen was available. 
The samples were stored at −20 °C (for analysis of melatonin and urea nitrogen), or −80 °C (for analysis of LC/MS 
metabolomics) as specified above, prior to being shipped on dry ice to the UK (University of Surrey) for analysis.
Sample processing. Targeted metabolomic analysis. Two-hourly plasma samples (15.00 h–15.00 h) were 
measured using the AbsoluteIDQ® p180 targeted metabolomics kit (Biocrates Life Sciences AG, Innsbruck, 
Austria), and a Waters Xevo TQ-S mass spectrometer coupled to an Acquity UPLC system (Waters Corporation, 
Milford, MA, USA). Plasma samples (10 μl) were prepared according to the manufacturer’s instructions adding 
several stable isotope–labelled standards to the samples prior to the derivatisation and extraction steps. Using 
either LC/MS (liquid chromatography/mass spectrometry) or FIA/MS (flow injection analysis/MS), up to 183 
metabolites from 5 different compound classes (namely acylcarnitines, amino acids, biogenic amines, glycero-
phospholipids and sphingolipids) can be quantified29.
Sample order was randomised and 3 levels of quality controls (QC), run on each 96-well plate. The levels 
of metabolites present in each QC were compared to the expected values and the percent coefficient of varia-
tion (CV%) calculated. Data were normalised between batches using the results of quality control level 2 (QC2) 
repeats across the plate (n = 4) and between plates (n = 5) using Biocrates METIDQ software (QC2 correction). 
Metabolites where >25% concentrations were below the limit of detection (<LOD) or below lower limit of quan-
tification (≪LLOQ) or above limit of quantification (>LOQ) or blank out of range, or the QC2 coefficient of var-
iance was >30%, were excluded (n = 53). The remaining 130 quantified metabolites comprised 11 acylcarnitines, 
20 amino acids, 9 biogenic amines, 76 glycerophospholipids and 14 sphingolipids.
Urea measurement. When we saw the pronounced increase in Cit and Arg concentrations, we added urea meas-
urement to our testing protocol. Urea nitrogen measurements were performed on hourly plasma samples across 
25 hours using the ADVIA® 1800 Chemistry System (Siemens Healthcare Diagnostics Inc., Camberley, UK), 
method based on the Roch-Ramel enzymatic reaction using urease and glutamate dehydrogenase. The inter-assay 
www.nature.com/scientificreports/
1 4Scientific RepoRts | 7:43030 | DOI: 10.1038/srep43030
coefficients of variation (CVs) for the plasma urea nitrogen assay were 4.5% at 3.0 mmol/L, 1.5% at 10.2 mmol/L 
and 1.5% at 19.4 mmol/L (n = 6 at each concentration).
Melatonin. Melatonin concentrations were measured on hourly plasma samples by radioimmunoassay as pre-
viously described73. Melatonin antibody was obtained from Stockgrand Ltd., melatonin measurements were per-
formed by Surrey Assays Ltd (University of Surrey). The limit of detection for the plasma melatonin assay was 
3.9 ± 0.8 pg/ml (mean ± SD). The interassay coefficients of variation (CVs) were 11.1% at 13.2 pg/ml, 8.9% at 
73.8 pg/ml and 7.2% at 95.3 pg/ml (n = 15 at each concentration). The time of melatonin onset (dim light mel-
atonin onset, DLMO) was calculated using the 25%-threshold method as previously described74. In order to 
control for any inter-animal differences in circadian phase, all the metabolite data were plotted with respect to 
each animal’s dim light melatonin onset time (DLMO), considered a reliable marker of circadian phase, rather 
than clock time of day. (In the figures presented, DLMO was annotated as zero; mean (±SEM) was 20.9 ± 0.9 h 
≈21.00 h).
Data analyses. Multivariate analysis was performed by principal component analysis (PCA) and orthogonal-
ized partial least squares discriminant analysis (OPLS-DA), using SIMCA-P v12.0 software (Umetrics, Sweden) 
and default software settings. The PCA algorithm75 transforms the data into a smaller number of dimensions 
(components) so that the main variation in the data can be visualized in a figure with a smaller number of dimen-
sions. Whereas PCA looks at overall variation (unsupervised), OPLS-DA distinguishes between class-predictive 
(discriminating) variation (supervised) and non-predictive (orthogonal) variation76,77. The combined use of these 
methods allows insight into the extent and underlying patterns of class-predictive variation within the data set 
as a whole.
Differences in individual metabolite levels were analysed in R version 3.1.2 using the linear models and 
ANOVA methods in the stats package. Linear models were fitted to the genotype and time of day (13 time 
points), with the animal as covariate. Significant differences for time of day, genotype, and their interaction 
were determined using 2-way ANOVA. P-values were corrected for multiple comparisons according to the 
Benjamini-Hochberg False Discovery Rate (FDR). Metabolites were considered as significant at a FDR cut off 
<0.05. For testing statistical significance, missing values (<1.2%) were not taken into account.
For data visualisation we used a heat map combined with hierarchical clustering (Euclidean distance and Ward 
linkage). Quantitative enrichment analysis (QEA) was performed using MetaboAnalyst 3.0 (www.metaboanalyst.
ca)42. A metabolite concentration (μM) table was inputted, with metabolite names standardised by a built-in tool 
so that these could be compared with the metabolite set library. The enrichment analysis used a generalised linear 
model to estimate a Q-statistic (correlation between metabolite concentration and clinical outcomes) for each 
metabolite set. P-values and corresponding FDR for each metabolic pathway-associated metabolite set that was 
enriched were calculated.
Prediction models based on combinations of metabolites were made by logistic modelling in R statistical soft-
ware. First, metabolites were selected that met the following criteria: a significant (FDR <0.05) difference between 
the control and HD group in the ANOVA model; a (non-cross-validated) Area Under the Curve (AUC) that 
was significantly higher than for randomly permutated values (p < 0.05, determined by 10,000 permutations); 
and a difference in plasma concentration of more than 5% between control and HD sheep. For the 37 markers 
that met these criteria, logistic models were made using log-transformed values. Missing values were imputed 
as the average value across all samples for that metabolite. To allow for models that would be robust to real-life 
situations (i.e. sampling can occur at any time point, predictions apply to animals rather than samples), models 
did not include time as a parameter. The predictive performance of the models was tested by determining the 
AUC using leave-one-sheep-out cross-validation (LOSOCV), in which a model was trained using data of all time 
points of all-but-one sheep and tested on the time points of the remaining sheep. Using this approach, models 
were developed by stepwise testing the result of adding another metabolite to the current model and selecting 
the metabolite with the highest gain in AUC to be included in the model for the next step. This was repeated 
until no further improvement in AUC could be achieved. For the eight models obtained (containing one to eight 
metabolites), predictions were further compared by Receiver Operating Characteristic (ROC) visualisation and 
determining the predicted sensitivity (detection rate) for a fixed 90% specificity (i.e. 10% false positive rate). In 
order to determine which time point best discriminates the control and HD groups AUC values for the models 
were also determined for each time point.
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